- Home
- AGMH vs SCYX Comparison
AGMH vs SCYX Comparison
Compare AGMH & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGMH
- SCYX
- Stock Information
- Founded
- AGMH 2015
- SCYX 1999
- Country
- AGMH Hong Kong
- SCYX United States
- Employees
- AGMH N/A
- SCYX N/A
- Industry
- AGMH EDP Services
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- AGMH Technology
- SCYX Health Care
- Exchange
- AGMH Nasdaq
- SCYX Nasdaq
- Market Cap
- AGMH 42.4M
- SCYX 50.3M
- IPO Year
- AGMH 2018
- SCYX 2014
- Fundamental
- Price
- AGMH $1.72
- SCYX $1.25
- Analyst Decision
- AGMH
- SCYX Buy
- Analyst Count
- AGMH 0
- SCYX 1
- Target Price
- AGMH N/A
- SCYX N/A
- AVG Volume (30 Days)
- AGMH 57.4K
- SCYX 183.1K
- Earning Date
- AGMH 12-27-2024
- SCYX 11-06-2024
- Dividend Yield
- AGMH N/A
- SCYX N/A
- EPS Growth
- AGMH N/A
- SCYX N/A
- EPS
- AGMH N/A
- SCYX N/A
- Revenue
- AGMH $92,907,172.00
- SCYX $8,566,000.00
- Revenue This Year
- AGMH N/A
- SCYX N/A
- Revenue Next Year
- AGMH N/A
- SCYX $145.59
- P/E Ratio
- AGMH N/A
- SCYX N/A
- Revenue Growth
- AGMH N/A
- SCYX N/A
- 52 Week Low
- AGMH $0.47
- SCYX $1.22
- 52 Week High
- AGMH $2.20
- SCYX $3.07
- Technical
- Relative Strength Index (RSI)
- AGMH 51.43
- SCYX 34.86
- Support Level
- AGMH $1.68
- SCYX $1.25
- Resistance Level
- AGMH $1.88
- SCYX $1.37
- Average True Range (ATR)
- AGMH 0.13
- SCYX 0.07
- MACD
- AGMH -0.02
- SCYX -0.01
- Stochastic Oscillator
- AGMH 32.36
- SCYX 9.52
About AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an investment holding company. The company focuses on blockchain-oriented ASIC chip design; high-end crypto miner production and fintech technology software service. It generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.